20,926 Shares in Medpace Holdings, Inc. $MEDP Bought by Man Group plc

Man Group plc purchased a new stake in Medpace Holdings, Inc. (NASDAQ:MEDP) in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 20,926 shares of the company’s stock, valued at approximately $11,082,000.

Other large investors have also bought and sold shares of the company. Roberts Glore & Co. Inc. IL purchased a new position in Medpace during the 2nd quarter worth $2,039,000. Polar Asset Management Partners Inc. purchased a new stake in shares of Medpace in the second quarter valued at about $236,000. Jupiter Topco LLC bought a new position in shares of Medpace during the second quarter valued at about $69,402,000. Hsbc Holdings PLC bought a new position in shares of Medpace during the second quarter valued at about $518,000. Finally, PDT Partners LLC bought a new position in shares of Medpace during the second quarter valued at about $3,366,000. 77.98% of the stock is currently owned by institutional investors.

Insider Activity at Medpace

In related news, Director Fred B. Davenport, Jr. sold 7,283 shares of the company’s stock in a transaction that occurred on Wednesday, August 19th. The stock was sold at an average price of $606.15, for a total value of $4,414,590.45. Following the transaction, the director owned 3,798 shares in the company, valued at approximately $2,302,157.70. This represents a 65.73% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO August J. Troendle sold 27,174 shares of the company’s stock in a transaction that occurred on Thursday, August 20th. The shares were sold at an average price of $618.79, for a total value of $16,814,999.46. Following the completion of the transaction, the chief executive officer owned 561,195 shares in the company, valued at approximately $347,261,854.05. The trade was a 4.62% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 133,821 shares of company stock valued at $81,748,135 over the last quarter. 20.50% of the stock is currently owned by insiders.

Medpace Stock Performance

Shares of NASDAQ:MEDP opened at $600.65 on Friday. The company has a market capitalization of $16.76 billion, a P/E ratio of 35.21, a price-to-earnings-growth ratio of 2.73 and a beta of 1.15. The company’s 50-day moving average is $565.33 and its 200 day moving average is $494.55. Medpace Holdings, Inc. has a fifty-two week low of $373.00 and a fifty-two week high of $677.90.

Medpace (NASDAQ:MEDP) last posted its quarterly earnings data on Wednesday, July 22nd. The company reported $4.25 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.98 by $0.27. The business had revenue of $707.33 million during the quarter, compared to the consensus estimate of $689.51 million. Medpace had a net margin of 17.67% and a return on equity of 110.15%. The firm’s quarterly revenue was up 17.2% compared to the same quarter last year. During the same quarter last year, the company posted $3.10 earnings per share. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. As a group, research analysts predict that Medpace Holdings, Inc. will post 17.54 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on MEDP. Mizuho upped their price objective on shares of Medpace from $586.00 to $665.00 and gave the stock an “outperform” rating in a research report on Friday, July 24th. TD Cowen lifted their target price on shares of Medpace from $419.00 to $492.00 and gave the stock a “hold” rating in a research report on Friday, July 24th. Leerink Partners set a $620.00 target price on Medpace in a research note on Thursday, July 23rd. Barclays set a $600.00 target price on Medpace in a report on Thursday, July 23rd. Finally, Truist Financial increased their price target on Medpace from $462.00 to $609.00 and gave the company a “hold” rating in a research report on Friday, July 24th. Three research analysts have rated the stock with a Buy rating and ten have given a Hold rating to the company. According to MarketBeat, Medpace has an average rating of “Hold” and an average target price of $584.18.

About Medpace

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.